PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces First Quarter 2018 Financial Results
- Landmark AdVance Study Demonstrates Strong Correlation Between  Adenovirus Burden and Mortality Risk - - Site Initiations for AdAPT Study of Oral Short-course Brincidofovir for Adenovirus and IV Brincidofovir Programs Are Progressing – - First Presentation on CMX521 for Norovirus in June- -
View HTML
Toggle Summary Chimerix to Present at the Deutsche Bank 43rd Annual Health Care Conference
DURHAM, N.C. , May 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will
View HTML
Toggle Summary Chimerix to Announce First Quarter 2018 Financial Results on May 7, 2018
DURHAM, N.C. , April 30, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Monday, May 7, 2018 at 8:30 a.m.
View HTML
Toggle Summary Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference
DURHAM, N.C. , April 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett Nichols , M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C.
View HTML
Toggle Summary Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors
DURHAM, N.C. , March 29, 2018 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the appointment of Martha J. Demski as Chair of the Board of Directors. Martha will succeed Ernest Mario , PhD, who is
View HTML
Toggle Summary The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality Risk
European, multi-center study reinforces need for effective therapies for adenovirus in immunocompromised patients DURHAM, N.C. , March 19, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 38th Annual Health Care Conference
DURHAM, N.C. , March 07, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey , M.D., M.P.H, President and Chief Executive Officer of Chimerix, will
View HTML
Toggle Summary Chimerix Announces Fourth Quarter and Full Year 2017 Financial Results
- AdVance Data to be Presented at EBMT Annual Meeting - - Oral and IV BCV Programs Remain on Track -   - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , March 01, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical
View HTML
Toggle Summary Chimerix to Announce Fourth Quarter and Full Year 2017 Financial Results on March 1, 2018
DURHAM, N.C. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Thursday, March 1, 2018 at
View HTML
Toggle Summary Chimerix Initiates AdAPT Study for Oral Brincidofovir and Advances IV Brincidofovir to Patient Studies
- Pivotal AdAPT Study of Oral Brincidofovir for Adenovirus Now Enrolling -  - No GI Adverse Effects for IV Brincidofovir 10 mg - - Announces First Antiviral Specific for Norovirus Now In Clinical Testing - DURHAM, N.C. , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical
View HTML